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Magic angle spinning (MAS) NMR has been used to inves-
tigate the location and orientation of five serotonin receptor
1a agonists (serotonin, buspirone, quipazine, 8-OH-DPAT,
and LY-163,165) in single component model lipid and brain
lipid membranes. The agonist locations are probed by moni-
toring changes in the lipid proton chemical shifts and by
MAS-assisted nuclear Overhauser enhancement spectros-
copy, which indicates the orientation of the agonists with
respect to the 1,2-dioleoyl-sn-glycero-3-phosphocholine lip-
ids. In the single component bilayer, the membrane agonists
are found predominantly in the top of the hydrophobic chain
or in the glycerol region of the membrane. Most of the ago-
nists orient approximately parallel to the membrane plane,
with the exception of quipazine, whose piperazine ring is
found in the glycerol region, whereas its benzene ring is
located within the lipid hydrophobic chain. The location of
the agonist in brain lipid membranes is similar to the 1,2-
dioleoyl-sn-glycero-3-phosphocholine lipid bilayers; how-
ever, many of the agonists appear to locate close to the cho-
lesterol in the membrane in preference to the phospholipids.
Drug molecule interaction with lipid membranes is a critical
factor governing its final activity, because it needs to negotiate
its way through several membranes on the way to its receptor
protein. In an effort to facilitate the design of drugs, water/
octanol partitioning coefficients are often used. However, this
simple two-phasemodel falls short of adequately describing the
complexity of lipid/drug interactions. A lipid membrane is a
chemically very diverse environment. Lipid headgroups are
often charged and highly hydrated, and the interface between
the headgroup and hydrophobic core of a membrane is typified
by the presence of glycerol, carbonyl groups, and lower concen-
trations of water. It is only the very center of themembrane that
is nonpolar and excludes water (1, 2).
Drug molecules tend to contain substituted aromatic
groups that add further complications; steric effects exclude
aromatic groups from the lipid chain region (3), whereas
other attractive forces between the ring and lipid carbonyls
draw the molecule to the interface between the chain and
headgroup regions of the membrane (4, 5). Furthermore, any
charged chemical groups will be excluded from the low
dielectric environment at the center of the bilayer (2). Con-
sequently, the mechanism by which a molecule partitions
into lipid bilayers or crosses a biological membrane will be a
complex interplay of many factors.
The majority of drug targets are membrane proteins.
Hence the interaction of a drug with the membrane is crucial
for its efficacy and involves several interesting aspects, such
as its location probability profile across the membrane
bilayer, its orientation, and its structure. A high location
probability in a particular part of a membrane and its orien-
tation with respect to the membrane normal could well be
important to how the drug is presented to the binding site of
the target protein (6).
Finally, it is now recognized that cholesterol-rich microdo-
mains (“lipid rafts”) form within cellular membranes (7). Cer-
tain chemicals have displayed an affinity for such domains (8),
and it is quite possible that such domains could have an impact
on receptor drug interactions.
Surprisingly little high resolution information exists on the
location profiles of drug molecules in lipid bilayers. Recently,
1HNMR and specificallymagic angle spinning-assisted nuclear
Overhauser enhancement spectroscopy (MAS-NOESY)2
experiments have proved to be an ideal tool for investigating
the location of small molecules embedded in lipid membranes,
with atomic resolution (3, 9, 10).
In this study, solid state NMR techniques are applied to
DOPC and brain lipid bilayers doped with five diverse 5-HT1a
receptor agonists (serotonin, buspirone, quipazine, 8-OH-
DPAT, and LY-165,163). These molecules represent a cross-
section of available serotonin receptor 1a (5-HT1a) agonists and
have varying octanol/water partitioning coefficients and
5-HT1a binding constants (see Table 1). The artificial agonist
interactions with membranes are of particular interest because
they must cross the blood-brain barrier to access their target
protein.Moreover, the natural binding site for serotonin on the
5-HT1a receptor is thought to be located within the membrane
and is consequently accessible only to molecules that accumu-
late in the surrounding lipids (11).
We present high resolution MAS-NOESY data of doped
DOPC membranes, which determine the agonist locations
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and orientation within the membrane bilayer. Chemical shift
changes, induced by agonist aromatic rings in proximate
lipid molecules, are used as a further indication of the drug
molecules membrane coordinates. Interestingly, it was pos-
sible to show that the agonists preferentially interact with
different components of the brain lipid systems.
EXPERIMENTAL PROCEDURES
Materials—1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC)
and porcine brain total lipid extracts were purchased from
Avanti Polar Lipids (Alabaster, AL). The brain lipid extract
consists of phosphatidylethanolamine (16.7% w/w), phos-
phatidylserine (10.6% w/w), phosphatidylcholine (9.6%
w/w), phosphatidic acid (2.8% w/w), phosphatidylinositol
(1.6%), and other (58.7% w/w) (Avanti Polar Lipids), of which
the majority will be cholesterol (!30–40% w/w total lipid)
(13). All other chemicals including serotonin, buspirone,
quipazine, 8-OH-DPAT, and LY-165,163 were purchased
from Sigma.
Sample Preparation—78 mg of DOPC and agonist was dis-
solved in chloroform/methanol (1:1 v/v) with a 4:1 lipid to ago-
nist molar ratio. Brain lipid/agonist samples were prepared at
the same ratios. The solvents were evaporated under vacuum,
and the resulting lipid cake was suspended in 1 ml of doubly
distilled water, frozen in liquid nitrogen, and then lyophilized
overnight under high vacuum. The dry lipid mixtures were
hydrated with !20 !l of D2O and then subjected to three
freeze/thaw cycles. The mixtures were then transferred into
4-mmMAS rotors.
NMRMeasurements—All NMR experiments (at 288 K) were
carried out on a Bruker Avance II 500MHz spectrometer using
a 4-mmMAS probe operating at frequencies of 500.1025 MHz
(1H) and 125.7546 MHz (13C). 1H and 13C experiments were
carried out at 10 kHz (1H) and 5 kHz (13C) MAS speeds. 1H
and 13C spectra were externally referenced to tetramethylsi-
lane at 0 ppm.
1H experiments were conducted with a typical "/2 pulse
length of 7 !s and a relaxation delay of 4 s. Two-dimensional
NOESY and correlation spectroscopy experiments had 256 or
512 increments and 8 or 16 scans/increment. NOESY build-up
curves were acquired at mixing times of 0.01, 0.05, 0.1, 0.2, 0.3,
0.4, 0.6, and 0.8 s.
13C spectra were collected with a typical "/2 pulse of 3.2
!s. Proton decoupling during the acquisition period was
achieved using two pulse phase modulation (30 kHz). Two-
dimensional 13C-1H heteronuclear correlation spectroscopy
(HETCOR) measurements were typically carried out with
256 increments and 256 or 512 scans/increment. A recycle
delay of 2 s was used for all 13C-detected experiments. Lipid
order parameters were determined by measuring 1H-13C
dipolar couplings using two-dimensional dipolar recoupling
on-axis with scaling and shape preservation (DROSS) exper-
iments (14). 1H-13C dipolar couplings were extracted from
the dipolar splittings directly from the spectrum. The split-
tings were converted to segmental order parameters as
described by Warschawski and Devaux (15).
All of the NMR data were processed using Topspin version
1.3 (Bruker Instruments, Karlsruhe, Germany). NOESY peak
volumes were obtained by peak fitting and integration using
CARA (16).
Data Analysis—NOESY data were used to calculate the loca-
tion of a given nucleus in the lipid membrane using the “full
matrix rate analysis,” described in detail by Huster et al. (17). In
short, experimentally measured NOESY peak volume, repre-
sented by matrix A, at the mixing time tm, and the cross-relax-
ation rate R are linked by the following matrix equation.
A"tm## A"0# " exp"$Rtm# (Eq. 1)
The relaxation rate matrix R is calculated by rewriting Eq. 1
as follows.
R # $
X"ln D#X$1
tm
(Eq. 2)
Here, X is the matrix of eigenvectors, and D is the diagonal
matrix of eigenvalues of the normalized peak volume matrix
a(tm)% A(tm)[(A(0)$1].
The relaxation rates, contained in R, were taken as indicators
of the relative location probabilities and are plotted to give a
location profile of the agonists, at atomic resolution.
All calculations were carried out with the help of Python 2.5,
specifically with the modules pylab and SciPy (www.scipy.org).
RESULTS
The agonist to lipid ratio (1:4) used in this study is desir-
able to ensure good signal to noise of the NOESY cross-peaks
and significant induced chemical shifts (see below). How-
ever, at these high agonist concentrations, measurements
may be compromised by disruption of the lipid bilayer or
agonist aggregation. Aggregation can be ruled out by the
observation that agonist proton peaks are sharp and well
resolved (Fig. 1, A–E), indicating that they are highly mobile.
The line widths of the lipid proton signals are unaffected by
the presence of agonist. It is well established that a change
from a fluid lamellar to a gel phase is accompanied by a
broadening of the NMR lines and subsequent loss of resolu-
tion (19, 20). Because no broadening is seen upon the addi-
tion of agonist (Fig. 1), it is safe to assume that the lipids, in
all mixtures, remain in a fluid lamellar phase.
The phase of the lipids was further investigated by determin-
ing the order parameters of all DOPC/agonist mixtures. These
values were extracted from 13C-1H dipolar couplings using a
DROSS pulse sequence (14, 15) as opposed to the more well
described 2H measurements. The order parameters of all ago-
FIGURE 1. 1H NMR spectra of DOPC/D2O dispersion doped with 25 mol % of various 5HT1a receptor agonists. A–E, DOPC/D2O dispersions doped with
serotonin, LY-165,163, quipazine, 8-OH-DPAT, andbuspirone, respectively. The aromatic signals from the agonist can be seenbetween 6 and 8ppm. The insets
in A–E show the structures of the relevant agonists along with assignments for two of the NMR signals corresponding to protons on opposite poles of the
molecule. F, DOPC without agonist. Assignments of the lipid signals are according to Yau et al. (3) and correspond to the labels on the lipid molecule in Fig. 4.
Peak a,$; peak b, chain CH2(n); peak c, C-3; peak d, C-8 and C-11; peak e, C-2; peak f, %; peak g, &; peak h, G-3; peak I, ' and G1; peak j, G1; peak k, HDO; peak l, C-9,
C-10, and G2.
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nist/DOPC mixtures (supplemental Fig. S1) are entirely con-
sistent with previously published figures of fluid lamellar lipids,
determined using the sameDROSS sequence (14, 15). It should
be noted that the order parameters derived from 2H NMR
experiments are systematically larger than those from DROSS
measurements (15).
One-dimensional 1H MAS NMR on Membranes Doped
with Agonist—Proton MAS spectra of DOPC lipid mem-
branes in the presence and absence of 5HT1a receptor ago-
nists are shown in Fig. 1. Assignments of the agonist signals
were carried out on the lipid/agonist mixtures using MAS-
correlation spectroscopy (data not shown) and MAS-
NOESY experiments. Full 1H NMR assignments were per-
formed. However, for the sake of simplicity, only two signal
assignments for each agonist (one for each pole of the mol-
ecule) will be used for the analysis.
1HNMRassignments for 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine determined elsewhere (3) were used for the
assignment of the DOPC signals. Althoughmost DOPC proton
resonances are resolved (Fig. 1F), it is worth noting that, of the
two G1 proton signals, one overlaps with the headgroup ' pro-
tons peak. In the following, the isolated peak at 4.49 ppm will
henceforth be referred to as the G1 signal.
1H MAS NMR spectra of the brain lipid membranes are, in
general,more convoluted thanDOPCspectra. This is due to the
higher complexity in composition of themembrane (see “Mate-
rials”). Broad lines and a narrow chemical shift dispersion result
in numerous overlapping resonances (data not shown).
1H NMR signals of the agonist aromatic moieties (Fig. 1,
A–E) are well resolved and downfield of the lipid resonances
(&6 ppm). Aliphatic agonist signals overlap with the stronger
lipid signals, with the exception ofCH3 protons of 8-OH-DPAT
(Fig. 1D, resonance 2), CH2 protons in the piperazine ring of
quipazine (Fig. 1C, resonance 1), and CH2 protons in the cyclo-
pentane ring of buspirone (Fig. 1E, resonance 2).
The presence of agonists in the lipid membrane causes shifts
in the lipid proton signals, because of the aromatic ring current
effect (3, 10, 21). The strength of the effect rises with the prox-
imity of the drugs aromatic rings to the lipid proton, whereas its
sign is dependent on the orientation of the ring relative to the
lipid proton. An analysis of these effects can indicate an average
location and orientation of the aromatic rings of an agonist
relative to the lipid molecules.
All agonists induce significant shifts in the lipid signals
(Fig. 2), most notably in between the top of the alkyl chains
and the headgroup. Serotonin and LY-165,163 cause large
shifts of the lipid headgroup resonances. All of the artificial
agonists also cause large shifts to the C-2 and C-3 protons.
Serotonin, buspirone, 8-OH-DPAT, and quipazine have very
little or no effect on the protons in the remainder of the lipid
chain. LY-165,163 is the only agonist that causes a significant
shift in all signals throughout the alkyl chain region, but like
the other molecules it has the largest effect on the C-2 and
C-3 protons.
In the DOPC membranes, all of the shifts are upfield (with
the exception of a small downfield shift in the G-3 protons of
serotonin-doped bilayers), indicating that the average location
of the lipid protons is above the agonist rings. These observa-
tions are in good agreement with similar studies where the
presence of tryprophan (3) and flavonoid analogs (10) produced
exclusively upfield shifts.
MAS-NOESY Measurements on DOPC Membranes Doped
withAgonist—AtypicalMAS-NOESY spectrumof serotonin in
DOPCmembranes is depicted in Fig. 3. Cross-peaks are visible
between all aromatic serotonin and DOPC resonances. The
build-up rates of the cross-peaks with increased mixing times
give an indication of the proximity of two protons (supplemen-
tal Fig. S2). Consequently, the location probability of a particu-
lar agonist proton in the lipid membrane can be determined
relative to other agonist protons. If multiple agonist proton sig-
nals are resolved (Fig. 1), the orientation of the molecule in the
membrane may be determined as well.
In general themaximum location probability for all aromatic
protons is located between the headgroup and alkyl chain
regions of themembrane (Fig. 4).Maximumpeak intensities for
all aromatic resonances are found between positions C-3 and
G-3 of the lipid chain, in agreement with similar studies of aro-
matic molecules in lipid membranes (3, 9, 10).
Quipazine and LY-165,163 show markedly different behav-
ior (Fig. 4, B and C). One end of the quipazine molecule has
intense cross-peaks occur between the aromatic ring protons
and the C-8 and C-11 groups situated half-way down the lipid
chain. However, like the other agonists, very small cross-peaks
are seen with the $-CH3 group at the end of the lipid chain.
LY-165,163 has significant cross-relaxation rates with the
whole of the lipidmolecule butwith themaximum still between
the C-3 and G-3 positions in the lipid chain. (Fig. 4B).
Proton signals fromopposite ends of the agonists indicate the
interaction with different parts of the lipid molecules. The
majority of the agonists shows only mildly different patterns of
cross-peak intensities for either end of the molecule.
In the case of serotonin, the ends of the molecules have a
maximum location probability in the glycerol region of the
membrane. The aromatic ring, however, has a distribution that
is located closer to the top of the alkyl chain, whereas the pyr-
role ring tends toward the headgroup (Fig. 4A).
The aromatic ring of 8-OH-DPAT has a strong preference
for the top of the alkyl chain, whereas its CH3 groups have a
broad distribution stretching from the lipid C-3 group to the &
CH2 in the headgroup (Fig. 4D). This would suggest that the
alkyl chains ofDPATare highlymobile and donot have a strong
location preference.
Both the aromatic and isopentane groups of buspirone have
location maxima in the glycerol region. However, the isopentane
also has a significant cross-peak with the '-CH2 protons in the
lipid headgroup (Fig. 4E), suggesting that buspirone has an angled
orientation,with the isopentane group locatedhigher in themem-
brane than the aromatic group.
The strongest orientation bias is exhibited by quipazine; the
aromatic ring is buried well within the hydrophobic chain, and
the piperazine ring has a strong preference for the glycerol
region (Fig. 4C). As a result quipazine appears to adopt an ori-
entation parallel with the lipids.
Most interestingly one end of LY-165,163 has two location
maxima. The trifluoromethylbenzene ring has a clear location
centered on the top of the lipid alkyl chain.However, the aniline
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FIGURE 2. Aromatic ring current induced chemical shifts of agonists in DOPC (gray) and brain lipid (black) bilayers for serotonin (A), LY-165,163 (B),
quipazine (C), 8-OH-DPAT (D), andbuspirone (E).DOPCdata are derived fromone-dimensional protonMASmeasurements. The brain lipid data are derived
from 13C-1H correlation measurements. F shows resonance assignments for cholesterol and DOPC.
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ring, at the opposite end of the molecule has two location max-
ima, one in the lipid head group and the other in the lower alkyl
chain region (Fig. 4B).
It should be noted that signals from agonist methylene
groups overlapping with the lipid signals may contribute to
cross-peak intensities. However, MAS-NOESY measurements
carried out at lower agonist concentrations (1:10 molar ratio)
(data not shown) resulted in similar distribution profiles, indi-
cating that this source of error is not of concern.
Two-dimensional 13CMASNMR on Brain LipidMembranes
Doped with Agonist—13C-detected NMR experiments offer
increased resolution over proton-detected experiments (Fig.
5A). By extending the 13C measurements into a second dimen-
sion, using HETCOR measurements, 13C chemical shifts may
be correlatedwith the chemical shifts of covalently bonded pro-
tons (Fig. 5B). The extra resolution of 13C measurements now
resolves individual proton resonances in the crowded spectra of
brain lipid membranes. The HETCOR spectra are further sim-
plified because quaternary 13C nuclei, with no bonded 1H
nuclei, do not appear in the spectrum.
13C lipid resonance assignments were based on previously
published MAS NMR studies (22) and confirmed by one-di-
mensional 13C spectra of DOPC and DOPC/cholesterol mix-
tures (data not shown). Phospholipid 13C and 1H signals of the
alkyl chain and glycerol groups and
phosphocholine and headgroups
were assigned. The C-2 protons
were not resolved in all brain lipid/
agonist mixtures. Furthermore, the
position of the alkene groups in the
chains of brain lipids are variable
and not good indicators of mem-
brane location. Consequently, pro-
tons on the C-2, alkene groups, and
carbons neighboring the alkene
groupswere omitted fromuse in the
analysis of brain lipid data.
Signals corresponding to the CH3
groups of cholesterol were easily
resolved and assigned, because of
their high signal intensities, com-
pared with other CH groups (Fig.
5B). Many signals arising from the
remaining cholesterol resonances
and other components of the mem-
brane were left unassigned. How-
ever, enough reliable assignments
exist for a comparison between the
neat DOPC lipid bilayers and the
brain lipids.
As found for experiments with
bilayers consisting of neat DOPC
lipids, introducing agonists to brain
lipid bilayers causes changes in lipid
proton chemical shifts. The magni-
tude of the peak shifts is illustrated
in Fig. 6, where peak shifts are
induced by the presence of sero-
tonin (Fig. 6, where peaks without serotonin are black, and
those with serotonin are blue). These results are summarized in
Fig. 2, where they are directly compared with the induced
chemical shift data in the DOPC measurements reported
above.
Overall, the agonist-induced chemical shifts on phospho-
lipid protons in brain lipids indicate similar effects to those
seen in pure DOPC membranes; only very small shift
changes occur in the alkyl chain region of the membrane,
larger changes are seen for the interface and phosphocholine
headgroup resonances (Fig. 2). The only notable differences
between the induced chemical shifts changes in brain lipids
as compared with DOPC membranes occur with quipazine
(Fig. 2C) and LY-163,165 (Fig. 2B) doped membranes. For
the latter, the C-3 protons no longer experience shift
changes significantly greater than other headgroup or inter-
facial protons, whereas for LY-163,165 doped brain lipid
membranes, the alkyl chain below the C-3 group does not
undergo any induced chemical shifts. It is worth noting that
in brain lipid membranes more protons are shifted down-
field by the presence of agonist. This is particularly evident
in the glycerol region of LY-163,165 doped membranes (Fig.
2B) and in the alkyl chain region of quipazine, 8-OH-DPAT,
and buspirone doped membranes (Fig. 2, B and C). Although
FIGURE 3. Two-dimensional 1H MAS NMR NOESY spectrum of DOPCmembranes doped with serotonin.
The lipid signals can be seen between 0 and 6 ppm. The aromatic signals from serotonin are between 6 and 8
ppmandarewell separated fromthe lipid signals. The cross-peaksbetween lipid and serotonin signals give the
location of the serotonin in the membrane.
5-HT1a Agonist Locations in LipidMembranes
7818 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 12•MARCH 21, 2008
 at Frankfurt University Library / Section Bibliothekszentrum
 Niederursel on M
arch 20, 2008 
www.jbc.org
Downloaded from
 
the downfield shifts are minor ('0.02 ppm), their presence
is significant, because downfield shifts are largely absent
from the DOPC doped membranes, nor are they seen in
comparable studies of doped single component membranes
(3, 10).
Well resolved cholesterol proton signals enable the extrac-
tion of information on the interactions between the sterol and
agonists (Fig. 5B). The induced chemical shifts experienced by
the cholesterol protons follow the samepattern as the phospho-
lipid protons. The smallest changes are experienced by the
groups situated closest to the bilayer center. Interestingly, ago-
nists often cause comparable and in two cases larger shifts in
the cholesterol protons than the phospholipid protons. This is
especially noticeable for quipazine and 8-OH-DPAT doped
membranes, where the magnitude of the cholesterol-induced
chemical shifts is two to three times that experienced by the
phospholipids protons (Fig. 2, C and D).
A striking exception to the upfield (or small downfield) shifts
was observed for cholesterol in the 8-OH-DPAT doped brain
lipid membranes (Fig. 2D). Both the 21c and 18c protons expe-
rienced downfield shifts, where the
18c shift change was particularly
pronounced (!0.08 ppm).
DISCUSSION
Thiswork compares the locations
of 5-HT1a receptor agonists in neat
component membranes and multi-
component brain lipid membranes.
The data give an indication as to
how the membrane environment
affects the way agonists may be
delivered and presented to target
proteins.
The NOESY data show that the
majority of the agonists have the
highest location probability within
the interface between the chain and
headgroup regions. Furthermore,
the agonist molecules lie with their
long axis approximately parallel to
the membrane plane (data summa-
rized in Fig. 7).
Quipazine is located deeper in the
membrane (the quipazine benzene
ring has its highest location proba-
bility in the upper alkyl chain
region) and has a strong orientation
bias that puts it perpendicular to the
membrane plane.
Interestingly LY-165,163 has an
unusual location behavior. It has a
significant population throughout
the whole lipid bilayer, and the ani-
line ring has two locationmaxima at
opposite ends of the lipid chain.
The agonist aromatic rings alter
the surrounding chemical environ-
ment, whichmanifests itself as a change in the chemical shift of
proximate lipid proton NMR signals and provides a second
indication for measuring the molecules location in the mem-
brane. These induced chemical shift data, for both DOPC and
brain lipids, broadly agree with the NOESY data; the agonists
preferentially locate between the top of the alkyl chain and the
choline headgroup.
Some features of the induced chemical shift data are worth
further discussion. First, the glycerol proton resonances expe-
rience very small agonist-induced chemical shifts, despite the
fact that the NOESY data place the location of the agonists
squarely in this region of the bilayer. Similar studies (with
indole derivatives) (3) reported the samediscrepancies between
chemical shifts and NOESY data. This is likely to be due to the
tight packing in this part of themembrane along with the prox-
imity of lipid carbonyl group shielding, which produces a sim-
ilar chemical environment to the agonist aromatic rings (23).
Hence, the presence of the agonist does not cause a significant
change in the glycerol proton environment, making glycerol
protons insensitive to aromatic induced chemical shifts. As a
FIGURE 4. Cross-relaxation rates between DOPC and agonists derived fromMAS-NOESYmeasurements
for serotonin (A), LY-165,163 (B), quipazine (C), 8-OH-DPAT (D), andbuspirone (E) inDOPCbilayers.Black
and gray bars represents positions 1 and 2 of each agonist as defined in Fig. 1, respectively. Black bars use the
left axes, and gray bars use the right axes.
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result, the induced chemical shifts of the glycerol resonances
may under-represent the concentration of agonists in this part
of the membrane.
Serotonin induces large chemical shifts in the choline proton
resonances of both DOPC and brain lipid bilayers. This is likely
due to thewater-soluble serotonin located in the aqueous phase
surrounding the highly hydrated headgroup.
Interestingly, the artificial agonists interact with the choles-
terol in the brain lipid membrane to a similar or greater extent
thanwith phospholipids. This has implications for the accumu-
lation of the molecules in a membrane. Cholesterol is a major
component of some lipid microdomains (7). The fact that ago-
nists cause a significant change in the chemical environment
around the cholesterol implies that theymay preferentially par-
tition into lipid rafts. This may indicate how agonists cross the
blood-brain barrier, especially because it is well established that
ceramides (another component of lipid rafts) can modulate the
permeability of lipid membranes to small solutes, dyes, and
even proteins (24).
More information on the interaction between cholesterol
and the agonists can be extracted from the sign of the induced
chemical shift changes. Quipazine and LY-163,165 both cause
exclusively upfield shifts, indicating that the cholesterol pro-
tons are located above the plane of the agonists’ rings. The
cholesterol 18c and 19c CH3 protons stick up and out of the
plane of the sterol rings, whereas the 21c CH3 protons branch
out of the cholesterol alkyl chain. To achieve the upfield shifts,
quipazine and LY-163,165 must roll around the cholesterol
molecule. In contrast serotonin and buspirone cause a down-
field shift in protons on the alkyl chain and upfield shifts in the
CH3 groups substituted into the sterol rings. These results can
be explained if the plane of the agonist rings stack below the
sterol CH3 groups, whereas the mobile alkyl chain samples the
space at the edge of the agonists’ rings. Unlike the other ago-
nists, 8-OH-DPAT causes downfield shifts in both CH3 groups
on both the sterol ring and alkyl chain. This would seem to
imply that it sits alongside and in plane with the sterol ring. It
would therefore seem that although the agonists all interact (to
a greater or lesser extent) with cholesterol, they do so in quite
different ways, resulting in variable orientations relative to the
cholesterol.
The interfacial location of the agonists tested here may
appear at odds with the fact that the synthetic agonists are all
hydrophobic, as their water-octanol partitioning coefficients
(Table 1) would indicate. However, it has been demonstrated
numerous times that aromatic ring structures do not penetrate
into the chain region of lipid membranes (3, 9, 21). This has
been attributed to numerous factors, including the entropic
cost associated with intercalating a rigid ring structure into the
mobile chain region (3), the fact that asymmetric aromaticmol-
ecules have dipole moments that cannot easily be accommo-
dated in the nonpolar chain region of the lipid membrane (25),
and the enthalpic requirements of hydroxy, carbonyl, and other
substitutions on the ring to fulfill their hydrogen bonding
potential (26, 27) (which cannot be achieved in the lipid chain
region). Furthermore, bonding interactions between the" elec-
trons of the lipid carbonyl group and aromatic rings (4, 5) may
serve to anchor the agonists in the interface region (3, 10). The
resulting interplay between the hydrophobic effect that drives
the molecules into the hydrophobic core and a gamut of other
FIGURE 5. 13C-detected NMR spectra. A, one-dimensional 13C proton
decoupled MAS. B, two-dimensional 1H-13C HETCOR correlation experiment
for brain lipidmembranes. Pure brain lipidswith assignments are shown, and
the subscript cdenotes cholesterol resonances. Unlabeled resonances cannot
be confidently assigned.
FIGURE 6. HETCOR spectra showing the headgroup and glycerol reso-
nances from pure brain lipids (black) and brain lipids doped with sero-
tonin (blue). The induced proton chemical shifts caused by the presence of
serotonin can clearly be seen. The assignments of the peaks are shown.
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factors forces them to locate in hydrated regions of the
membrane.
An important factor governing bioefficiency is the ability of
the agonist to access the protein-binding site. To do this most
efficiently, it must accumulate in the membrane close to the
binding site and be presented to the protein in the correct ori-
entation. Serotonin, 8-OH-DPAT, and buspirone accumulate
in much the same region of the membrane and with similar
orientations, whereas LY-165,163 is muchmore evenly distrib-
uted through themembrane. Quipazine is the only agonist that
is oriented perpendicular to themembrane plane. It is therefore
striking that, of the agonists tested here, quipazine has by far the
lowest affinity for the 5-HT1a receptor. Most of the agonists
have low nanomolar dissociation constants (28, 29) (Table 1)
compared with 780 nM for quipazine (28). Quipazine orienta-
tion and locationmay go someway to explain its apparent lower
affinity for 5-HT1a. It may be that the preferred location and
orientation of quipazine makes it inaccessible to the protein-
binding site.
A further factor affecting the bioefficiency of an agonist will
be its preference for particular microdomains within a mem-
brane. It is becoming clear that some proteins preferentially
locate in particular microdomains (8, 30, 31). This raises the
possibility that a key factor in the bioactivity of agonists is the
ability to partition into the microdomain where their target
protein is located. Indeed it is well known that the 5HT1a recep-
tor is modulated by cholesterol (11), and a recent study has
shown that it partitions into cholesterol-rich lipid rafts (8). This
is particularly pertinent for the agonists tested in this study
because they too interact with cholesterol and so may prefer-
entially partition into lipid rafts.
The system used here is a simplified model of the biological
membranes within which the target proteins reside. However,
the data show that molecules targeting the same protein can
interact with a membrane in significantly different ways. Fur-
thermore, some of the agonists tested interact more favorably
with cholesterol than phospholipid components of brain lipid
membranes. This in turn implies that some agonists may pref-
erentially locate in cholesterol-rich lipid domains, where it has
also been shown that the target protein is located. It also raises
the intriguing possibility that themodulation of protein activity
by themembrane is not exclusively through lipid/protein inter-
actions but may also be due to lipid/drug interactions altering
the location and orientation of the protein agonists. Further
studies are underway to shed more light on the interactions
between cholesterol and the 5HT1a used in this study.
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